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Abstract: Cold pain is a frequent symptom in neuropathic pain. Compared to other pain 13
modalities, such as heat pain, the mechanisms behind physiological and pathological cold 14
pain remain elusive. Moreover, it is becoming increasingly evident that cold pain 15
pharmacology differs between various neuropathic pain conditions, making mechanism-16
directed treatment based on an understanding of the underlying pathophysiological 17
mechanisms imperative to achieving clinical success. Here we review the processes of 18
physiological and abnormal cold sensing, the pharmacology of cold nociception, cold 19
hyperalgesia and cold allodynia, and provide an overview of cold pain syndromes and their 20
current and potential treatments.21
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2
Introduction3
The perception of temperature is vital for human survival. As homoeothermic animals, 4
humans rely on temperature regulation mechanisms to maintain a constant body temperature 5
of ~ 37 °C irrespective of activity or the external environment. However, while innocuous hot 6
or cold is considered harmless and often pleasurable, temperature extremes are painful and 7
interpreted as signs of impeding tissue damage. The sensation of pleasant cool is usually 8
elicited at temperatures just below normal skin temperature (32 °C), with temperatures 9
approaching 10–15 °C and below gradually eliciting burning, aching and pricking pain [1-3]. 10
Indeed, many of us are familiar with the excruciating pain that follows consumption of cold 11
beverages or food, resulting in a cold-induced headache also known as “brain freeze”. 12
Similarly, immersion in ice-cold water is a commonly used nociceptive assessment in sensory 13
testing to quantify an individual’s pain threshold [4]. In this review, we describe the different 14
cold pain pathways, ion channels involved in cold pain signalling, their involvement in 15
pathological cold pain, and discuss mechanisms of current and potential new treatments for 16
cold pain that might alleviate chronic cold pain sensitisation.17
18
Cold pain pathways19
Specific peripheral nerves activated by innocuous cold were discovered almost a century 20
ago, first in the cat [5] and later in primates, where in vivo studies in anesthetised animal 21
identified peripheral nerve fibres that discharged action potentials in response to cold 22
stimulation of their receptive fields [6, 7]. Initially, these studies identified afferent fibres that 23
only responded to innocuous temperatures (below 27 °C) and not to heat or mechanical 24
stimuli. The firing frequency of these cold-sensitive neurons, later regarded as ‘classic’ 25
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innocuous cold thermosensors, is inversely proportional to temperature, with peak discharge 1
rates occurring on cooling between 30 and 25 °C [7]. Since this early discovery, other cold-2
sensitive sensory fibre subtypes were characterised in primates and in other species, as shown 3
in Table 1 [6-13]. Subsets of slow-conducting (typically < 1 m/s) C-fibres are monomodal 4
and sense innocuous and noxious cold or are multimodal mechanothermal nociceptors, with 5
the remaining cold-sensitive neurons classified as fast-conducting (up to 16 m/s) Aδ-fibres [3, 6
13-15]. Given that C-fibres sensitive to noxious cold are mostly polymodal nociceptors that 7
respond to other stimuli, including mechanical stimulation, it appears likely that C-fibres 8
conduct pain signals without discriminating the nature of the stimuli, while Aδ-fibres 9
recognise the discomfort is caused specifically by cold [7, 16]. It is thus very likely that the 10
full sensation of cold pain requires the presence of both C- and Aδ-fibres.11
In humans, the physiological cold pain threshold is significantly more variable than the 12
heat pain threshold, with temperatures below approximately 15 °C eliciting pain. Broadly, the 13
intensity of cold pain increases rapidly between approximately 20 and 0 °C [1, 2, 17]. In 14
rodents, frank nocifensive behaviour on contact exposure to cold surfaces is usually only 15
elicited at temperatures below 5 °C [18, 19], which may reflect the relative insensitivity of 16
these behavioural assays to detect mild to moderate pain-related behaviours in rodents. 17
Centrally, temperature signals reach the brain via the lateral spinothalamic tract, whereas 18
pain signals are additionally carried via the spinoreticular and spinothalamic tracts, which 19
terminate in the thalamus and the frontal cortices, respectively [20-23]. In healthy humans, 20
stimulation of the forearm skin with innocuous cold leads to activation of the contra- and 21
ipsilateral- posterior insular cortices as the primary somatosensory area [24]. In contrast, 22
noxious cold stimuli activate the contra- and ipsilateral- insular cortices and secondary 23
somatosensory cortices and the cingulate cortex, as revealed by magnetoencephalography 24
[24]. Functional magnetic resonance imaging has been employed to investigate brain areas 25
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activated during menthol-induced cold allodynia, identifying increased activation within the 1
ipsilateral dorsolateral prefrontal cortices and the brainstem (ipsilateral parabrachial nucleus) 2
[25]. These observations illustrate some of the differences between the brain regions 3
responsible for innocuous cold, cold pain, and pathological cold pain. In contrast, the 4
molecular mechanisms underlying central cold pain processing are less clear. Studies to date 5
have revealed that the beneficial effects of spinal cord stimulation were abolished by 6
serotonin receptor antagonists in a murine spinal nerve ligation model [26], and that ablating 7
neuropeptide Y receptors in the superficial spinal dorsal horn reduced cold allodynia in CFA-8
induced inflammation in rats [27].  Interestingly, µ-opioid receptor binding potential in the 9
striatum predicted cold pressor test threshold in humans, but not cold tolerance, possibly 10
correlating peripheral cold pain threshold with central opioid-dependent inhibition [28]. 11
12
Pathological Cold Pain Conditions13
Pathological cold pain is a frequent symptom in a range of neuropathic pain syndromes, 14
including those of peripheral and central origin, and usually presents as cold allodynia or 15
hyperalgesia [29]. While many conditions, including diabetic neuropathy, peripheral nerve 16
injury, chemotherapy-induced neuropathy, post-stroke central pain and ciguatera (see Table 17
2) can present with the symptom of pathological cold pain, the mechanisms by which cold 18
pain arise are still poorly understood and can vary significantly between diseases [30-35]. 19
A condition that is defined by cold allodynia is ciguatera, a form of marine food poisoning 20
arising from the consumption of tropical and subtropical fish contaminated with ciguatoxins. 21
Ciguatoxins originate from dinoflagellates of the Gambierdiscus family and accumulate in 22
reef fish through the marine food chain [36]. Symptoms of ciguatera include dysaesthesias, 23
headache, dental pain, and myalgia, with cold allodynia occurring in almost all ciguatera 24
patients (for review see [36]). Experiments with human volunteers showed that intracutaneous 25
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injection of ciguatoxin induced local cold allodynia which faded after a few hours, suggesting 1
ciguatoxin acts acutely and peripherally to cause cold pain [37]. Similarly, mice of the 2
C57BL/6 strain develop cold, but not mechanical or heat allodynia, within one hour after 3
intraplantar ciguatoxin injection, an effect that is mediated predominantly through peripheral 4
sensory neurons expressing the transient receptor potential (TRP) cold sensor TRPA1 [38].5
In contrast, cold allodynia elicited after intraplantar injection of the chemotherapeutic 6
agent oxaliplatin involved sensory neurons expressing voltage-gated sodium channel (Nav) 7
subtype 1.6 and voltage-gated potassium channel (Kv) channels, and developed independent 8
of cold-sensitive TRP channels [39]. While oxaliplatin is administered intravenously in 9
humans, intraplantar injection of oxaliplatin in mice recapitulated the immediate-onset cold-10
induced dysaesthesias that often occur in humans undergoing therapy with the platinum-11
derived anti-tumour agent. The immediate occurrence of painful symptoms after 12
subcutaneous oxaliplatin exposure in mice implies that primary sensory effects are sufficient 13
to elicit cold allodynia. However, the long-lasting progression of the disease in humans after 14
intravenous infusion does not exclude an altered expression of cold-sensing TRP channels 15
contributing or aggravating the disease at a later stage, as found for TRPA1 or TRPM8 in 16
mouse models of chronic oxaliplatin-induced neuropathy [40-43].17
Treatment with paclitaxel, a chemotherapy agent used in the management of solid tumours 18
such as breast cancer, is also associated with a high incidence of cold allodynia. Paclitaxel-19
induced cold allodynia commences in the hands and feet and gradually progresses centrally. 20
Cold allodynia appears to parallel the development of paclitaxel-induced neuropathy with 21
signs such as demyelination, accumulation of abnormal mitochondria in sensory nerves, and 22
fibre loss in severe cases [44, 45]. Subcutaneous injection of tetrodotoxin (TTX) reduced 23
paclitaxel-induced mechanical, heat and cold allodynia [46], suggesting the involvement of 24
TTX-sensitive Nav isoforms as observed for oxaliplatin-induced cold allodynia. 25
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Interestingly, diabetic animals with pre-existing peripheral neuropathy are more susceptible 1
to develop cold allodynia when treated with paclitaxel [45]. This is perhaps not surprising as 2
diabetic neuropathy, a late symptom of chronic diabetes, is in itself a complex neuropathic 3
pain syndrome associated with cold allodynia and increased TRPA1 gene expression. More 4
than 50% of patients diagnosed with diabetes will eventually develop diabetic neuropathy, 5
which is characterised by distal paraesthesias and dysaesthesias, including cold-induced 6
allodynia and hyperalgesia [47, 48]. The causes of diabetic neuropathy are multifactorial, 7
revolving around the cellular results of chronic hyperglycaemia which in turn cause oxidative 8
stress and cellular damage [49]. While the precise pathophysiological mechanisms leading to 9
cold pain in diabetic neuropathy remain to be elucidated, abnormal peripheral sensory nerve 10
function, including functional changes of the molecular players implicated in cold sensing, are 11
likely to be involved. For example, methylglyoxal, an endogenous reactive metabolite, 12
contributes to gain-of-function dysregulation of peripheral sensory neurons by increasing 13
signalling through voltage-gated sodium channels and the cold-sensitive receptor TRPA1 [50, 14
51].15
Cold intolerance also occurs in over 40% of patients with upper-extremity nerve trauma or 16
hand/finger amputation and in generalised pain states such as complex regional pain 17
syndrome, and may involv  both peripheral sensory neuron abnormalities as well as altered 18
central processing [52-55]. In addition to dysfunction of peripheral nerves, changes in central 19
signalling can also lead to cold allodynia. For example, central  post-stroke  pain (CPSP) is a 20
chronic pain condition [56, 57] that features painful symptoms in the body parts related to the 21
brain territory affected by the cerebrovascular lesion. Estimations about cold pain prevalence 22
are difficult because pre-existing chronic pain disorders are frequent [56]. Nevertheless, 23
thermal allodynia is a frequent sensory symptom of CPSP and the allodynia presumably arises 24
when CNS structures that form parts of somatosensory pathways, such as the medulla, 25
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thalamus, and cortex, are among damaged areas [56]. Interestingly, brain lesions alone are 1
insufficient to cause cold allodynia, suggesting additional secondary pathophysiological 2
changes contribute to the development of cold allodynia following a stroke [56].3
4
Ion Channels Involved in Cold Pain5
Cold temperature detection involves the process of sensory transduction in the cutaneous 6
primary sensory nerve terminals, which converts a thermal stimulus into depolarisation of the 7
membrane. This transformation into an electrical signal is followed by the subsequent 8
propagation of the action potentials in the cold-sensitive afferent nerves. A large array of ion 9
channels, including TRPs and sodium and potassium channels, shape this process as outlined 10
below (Fig. 1).11
12
TRP Channels13
Cold-sensitive TRPM8: The discovery of the transient receptor potential melastatin 8 14
channel (TRPM8) [58, 59] has significantly advanced our understanding of the processes 15
underlying transduction and transformation of external cold into electrical signals. The 16
channel is essential for the detection of environmental cold, and a series of potassium channels 17
contribute to threshold adjustment and amplification of TRPM8-dependent cold transduction 18
[60-62]. TRPM8-/- mice show drastically reduced responses to innocuous cold [63-65]. 19
Cultured trigeminal ganglia from TRPM8-/- mice are also insensitive to menthol or innocuous 20
cold (22 °C), while the number of cold-responsive cutaneous myelinated and unmyelinated 21
nerve endings is decreased significantly [63]. However, the extent to which TRPM8 is 22
essential for pathological forms of cold pain is controversial, and conflicting evidence exists, 23
as outlined in Table 3. 24
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TRPM8-/- mice, mice treated with intrathecal TRPM8 antisense oligonucleotide, and mice 1
with diphtheria toxin-mediated ablation of TRPM8-positive neurons all had reduced 2
physiological cold sensitivity, but also reduced cold hypersensitivity following Complete 3
Freund's Adjuvant (CFA)-induced inflammation and chronic constriction injury (CCI), as 4
examined by the acetone test [64, 66, 67]. At the same time, TRPM8-/- mice retain noxious 5
cold sensitivity and exhibit similar nocifensive behaviours to control mice at temperatures 6
below 10 °C [63, 65]. A further confounding factor in studies assessing the contribution of 7
TRPM8 to cold sensing and cold pain is the specificity and selectivity of pharmacological 8
“tool” compounds such as menthol. Many studies equate menthol-induced responses or effects 9
with selective TRPM8 activation. However, the prototypical TRPM8 agonist menthol, as 10
discussed below, is a promiscuous compound and elicits responses in TRPM8-negative 11
sensory neurons. Menthol inhibits nicotinic acetylcholine receptors [68], inactivates voltage-12
gated calcium currents [69], inhibits Kv7.2/7.3 channels [60], and activates and/or desensitises 13
the cold-sensitive TRPA1 channel [70].14
15
Cold-sensitive TRPA1: TRPA1 is considered a noxious cold and irritant sensor. The 16
channel mediates, among others, the reaction to the pungent components of mustard, 17
horseradish, and wasabi. TRPA1 is also activated by formaldehyde, bacterial endotoxins and 18
pro-inflammatory mediators such as bradykinin, methylglyoxal, and prostaglandin E2 [50, 71-19
79]. TRPA1 expression in sensory neuronal populations overlaps little with TRPM8 20
expression, suggesting distinct physiological functions for the two channels. Moreover, 21
TRPA1 is not only highly co-expressed with the noxious heat sensor TRPV1, but can also 22
form functional heteromultimers [80], which adds to the functional complexity of this channel.23
Activation of TRPA1 by cold in cellular models varies between species [81] and has been 24
investigated extensively, as summarised in Table 4. The overwhelming majority of studies 25
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assessed TRPA1 activation by cold using cultured rodent dorsal root ganglion (DRG) neurons, 1
or rodent TRPA1 overexpressed in mammalian HEK293 cells, CHO cells, or Xenopus 2
oocytes. Many such studies demonstrated increased intracellular Ca2+ or TRPA1-mediated 3
inward current upon exposure to cool temperatures (5-18 °C ; see Table 4) [59, 77, 81-86]. 4
However, while questions about the cold-sensitivity of TRPA1 have been raised [61, 74, 81, 5
87, 88], species- and tissue-specific differences in the cold sensitivity of TRPA1 are becoming 6
apparent. A number of studies also based their conclusions regarding the cold sensitivity of 7
TRP channels on the perhaps erroneous assumption of the pharmacological specificity of 8
isothioscyanates, icilin and menthol [59, 70, 74, 89-92]. In fact, while rodent TRPA1 is cold-9
sensitive, snake and drosophila TRPA1 are heat-sensitive [87, 93, 94]. In TRPA1-deficient 10
mice, altered nocifensive behaviour in various noxious cold tests has been described and is 11
summarised in Table 5. In addition, a recent functional MRI study unveiled altered central 12
processing of cold stimuli at temperatures above the noxious cold range (15 °C) where no 13
measurable aversive behaviour is observed, suggesting that standard cold pain tests in mice 14
are less sensitive than commonly believed [38]. In contrast to mice TRPA1, primate TRPA1 15
does not respond to cooling in in vitro systems [81]. Nevertheless, a distinct role for TRPA1 in 16
cold sensing and cold pain in humans cannot be denied, as a monogenic TRPA1 gain-of-17
function mutation is linked to a hereditary disease of episodic debilitating pain, which is 18
triggered by cold [95]. Turning to ciguatoxin as a model of cold allodynia, de novo TRPA1-19
mediated cold responses in previously cold-insensitive mouse DRG neurons emerged after 20
treatment with ciguatoxin and correlate well with a key contribution of TRPA1 to ciguatoxin-21
induced cold allodynia in mice [38]. Comparable mechanisms of TRPA1 sensitisation to cold 22
may apply for cold hypersensitivity in inflammatory conditions and diabetic neuropathy [50, 23
71, 83, 96]. In addition, evidence for TRPA1 contribution to neuropathic cold allodynia of 24
various origins is brought together in Table 5. 25
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Insight into the biophysical mechanisms underlying temperature-sensitivity of TRP 1
channels comes from a range of elegant studies assessing gating behavior of TRP channel 2
chimeras and orthologs. Although temperature can have a profound effect on general 3
phospholipid phase transitions, conformational changes, and protein denaturation, the 4
remarkable effect of temperature on thermo-TRP function likely arises from direct effects on 5
structural components which alter channel open probability [97]. In the case of TRPA1, 6
residues contributing to thermal sensitivity appear to be located in the region of the N-terminal 7
ankyrin domains which converted the cold-sensitive mouse TRPA1 into a heat-gated channel 8
akin to the rattlesnake TRPA1 ortholog [87, 98], while point mutations within the S5 and S6 9
transmembrane domain rendered rodent and drosophila TRPA1, respectively, temperature-10
insensitive [81, 99]. Similarly, replacement of the TRPM8 C-terminus with the corresponding 11
TRPV1 sequence reversed the temperature-dependence of the channel [100]. In addition, 12
temperature and voltage exert synergistic, or allosteric, effects on channel gating, with cooling 13
shifting the voltage-dependence of TRPM8 activation closer to physiological membrane 14
potential [101].15
16
Cold-sensitive TRPC5: The recent discovery of the involvement of the TRPC5 channel in 17
peripheral cold sensation has recently expanded the list of cold-sensitive channels [102] and 18
may provide an explanation for the TRPM8- and TRPA1-independent cold sensitivity 19
observed in peripheral sensory neurons [90]. TRPC5 homomers, but not TRPC5-TRPC1 20
heteromultimers, are most active between 37 and 25 °C [102]. In mice and humans, TRPC5 is 21
expressed at all levels of the nociceptive system, including sensory nerve endings, axons, 22
DRG neurons and the superficial nociceptive laminae in the spinal cord [102]. TRPC5-/- mice, 23
based on the 129S1/SvImJ strain, had fewer TRPM8-expressing DRG neurons but 24
significantly higher numbers of cutaneous CMC-fibres with increased sensitivity to cold and 25
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menthol. However, at the behavioural level, no differences appeared in the cold plate and the 1
two-plate temperature preference assays. Rather than being a noxious cold sensor, TRPC5 2
probably mediates changes in detection and regional adaption to cold. Cold-induced gating of 3
TRPC5 is potentiated by activation of Gq-coupled receptors, which modulates cold sensing by 4
TRPC5 [102]. Neither oxaliplatin nor ciguatoxin-activated models of cold allodynia involve 5
TRPC5 [38, 39] .6
7
Voltage-gated sodium channels8
Nav1.1, Nav1.2, Nav1.6, Nav1.7, Nav1.8 and Nav1.9 are the Nav isoforms expressed in adult 9
DRG neurons and co-localise to a variable degree with peripherin, a marker of non-myelinated 10
C-fibre neurons and with neurofilament, which stains medium and large diameter neurons 11
associated with A-fibres. While Nav1.6 localises to all sizes of neurons, Nav1.7, Nav1.8 and 12
Nav1.9 predominate the small neurons. In contrast, Nav1.1 is exclusively confined to large 13
neurons [103]. Nav1.3 is the major Nav subtype in embryonic neurons and is present in 14
sympathetic neurons [104], but undetectable in adult DRGs, where it re-emerges after injuries 15
such as axotomy [105]. Given their diverse roles in cold pain pathways, it is likely that these 16
subtypes contribute to modality- and pathway-specific pain, including nociceptive cold pain, 17
cold allodynia and cold hyp ralgesia as discussed below. 18
19
Nav1.7: Nav1.7 has gained prominence as a putative pain target, with rare genetic mutations 20
rendering Nav1.7 non-functional in humans causing cases of congenital insensitivity to pain 21
(CIP), without affecting the ability to discriminate hot from cold [106-109]. Its contribution to 22
physiological and pathological cold pain was assessed using three different Nav1.7 knockout 23
mouse strains (see Table 6): Nav1.7
Nav1.8, with Nav1.7 deleted from Nav1.8-expressing 24
neurons; Nav1.7
Advill, with Nav1.7 deleted from all sensory neurons; and Nav1.7
Wnt1, with 25
Page 13 of 50
Ac
ce
pte
d M
an
us
cri
pt
13
Nav1.7 deleted from sensory and sympathetic neurons [110]. Deletion of Nav1.7 from Nav1.8-1
expressing nociceptors reduced but did not abolish withdrawal responses to an acetone drop 2
applied to the hind paw, while cold nociception was virtually abolished in Nav1.7
Advill and3
Nav1.7
Wnt1 animals [110]. Although this suggests a crucial role for Nav1.7 in Nav1.8-negative 4
neurons during cold nociception, all three Nav1.7 knockout mouse lines displayed normal 5
temperature preference behaviour between 30 °C and 5 °C [110]. Additionally, Nav1.7 in 6
DRG neurons is essential for cold allodynia in the CCI-model of neuropathic pain, but not in 7
the sympathetically mediated spinal nerve transection (SNT) model of neuropathic pain, 8
which only requires Nav1.7 in sympathetic neurons. Consistent with these roles, Nav1.7 does 9
not contribute to oxaliplatin-induced cold allodynia [39, 111]. 10
11
Nav1.8: Low-threshold TTX-sensitive ion channels such as Nav1.7 enter a state of slow 12
inactivation upon cooling at temperatures lower than 26 °C [112]. In contrast, the high-13
threshold, slow TTX-resistant Nav1.8 is resistant to cold-induced slow inactivation and 14
remains available to generate action potentials at noxious cold temperatures. Consequentially, 15
Nav1.8 expressing C-fibres predominate our perceptions in cold temperatures, while A-fibre 16
mediated mechanosensitivity and manual dexterity is lost [112]. Thus, Nav1.8 is not only 17
responsible for pain caused by noxious cold, but also for any other pain modality at low 18
temperatures. Accordingly, cold pain thresholds are significantly increased in Nav1.8 global 19
knockout animals and after diphtheria toxin-mediated ablation of Nav1.8-expressing DRG 20
neurons [110, 112, 113] (see Table 7). Similar to Nav1.7, the contribution of Nav1.8 to 21
pathological cold pain appears to be modality- and disease-specific. In the post-CCI cold 22
allodynia model, Nav1.8 knock-out mice showed attenuated flinching responses to acetone, 23
while in the post-SNT cold allodynia model the withdrawal responses of Nav1.8 knock-out 24
animals were similar to wild-type litter mates [111]. 25
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Nav1.8 appears less important in conditions where cold allodynia occurs at more moderate 1
temperatures, potentially because TTX-sensitive Nav isoforms remain functional. This is likely 2
the case for ciguatoxin-induced cold allodynia, where Nav1.8-expressing C-fibre nociceptive 3
pathways contribute partially to cold pain behaviour in concert with TTX-sensitive ion4
channels on A-fibre pathways [38]. In contrast to ciguatoxin, cold allodynia elicited by 5
intraplantar injection of the chemotherapeutic agent oxaliplatin is mediated entirely by TTX-6
sensitive Nav isoforms, and cold pain behaviour at 10 °C was not affected in Nav1.8 knockout 7
animals, or after treatment with the Nav1.8 inhibitor A803467 [39]. These findings were also 8
confirmed in a more conventional model where cold allodynia develops slowly after repeated 9
intravenous administration of oxaliplatin [111] and which was independent of Nav1.7, Nav1.8, 10
and TRP channels. 11
12
Nav1.6 and Nav1.3: Involvement of Nav1.3 in pain behaviour seems minor, despite being 13
upregulated in various inflammatory and neuropathic pain conditions [114-116]. Some 14
contribution of Nav1.3 was shown in CCI, but not in the sciatic nerve ligation (SNL) or 15
oxaliplatin-induced models of cold allodynia [39, 111]. Indeed, oxaliplatin-induced cold 16
allodynia was completely abolished by TTX and the Nav1.6 inhibitor GIIIA, while inhibition 17
by subtype-selective modulators or genetic deletion of other Nav isoforms, including Nav1.7 18
and Nav1.3, had no effect [39]. Although activation of Nav1.6 by the scorpion toxin Cn2 was 19
not sufficient to cause cold allodynia, it amplified cold pain caused by potassium channel 20
inhibition [39]. Indeed, oxaliplatin is likely to elicit direct effects on Nav1.6-expressing 21
sensory neurons independent of changes in neuronal viability or frank neuronal toxicity. When 22
exposed to oxaliplatin, compound after-potentials were triggered in A-fibres from human 23
nerve fascicles upon cooling, but not in C-fibres [117]. This effect was abolished in sural 24
nerve fascicles from SCN8Amed/med mice that lack functional Nav1.6 [117]. Oxaliplatin also 25
Page 15 of 50
Ac
ce
pte
d M
an
us
cri
pt
15
induced Nav1.6-mediated resurgent and persistent currents in large (but not small) diameter 1
DRG neurons in response to cooling, and significantly slowed inactivation of heterologously 2
expressed Nav1.6 [117]. These effects corroborate a crucial role for Nav1.6 in cold pain 3
pathways. Indeed, the contribution of Nav1.6 to cold pain may extend to other conditions, as 4
ciguatoxin-induced cold allodynia was also partially inhibited by the Nav1.6 inhibitor GIIIA 5
[37].6
7
Potassium channels8
A range of potassium channels, including the two-pore domain (2PK) background channels 9
TRAAK, TASK-3, TREK-1, TRESK [118, 119] as well as voltage-gated potassium channels 10
Kv1 and Kv7.2/7.3, have been implicated in the physiology of cold sensing and the 11
pathophysiology of cold pain. Closure of background 2PK channels underpins cooling-12
induced increase in excitability of cultured DRG neurons, leading to membrane depolarisation 13
and increased firing [120, 121].14
TREK-1 and TRAAK are temperature- and mechano-sensitive background potassium 15
channels of the 2PK family [122, 123] that stabilise the resting membrane potential at normal 16
skin and body temperature. Their closure with cooling and heating facilitates temperature 17
transduction-induced membrane depolarisation in C-fibres [120, 121, 123, 124]. However, 18
while C-fibres from TREK-1 knock-out mice exhibit a reduced heat threshold, these mice did 19
not display any difference in cold sensitivity compared to control during the acetone test and 20
cold water tail immersion [124]. A more detailed analysis using temperature-controlled cold 21
plates revealed that TREK-1 knock-out mice had reduced cold avoidance at 18°C but not at 22
other temperatures [62], although cold allodynia (as evidenced by decreased paw withdrawal 23
responses in the acetone test) was decreased in TREK-1-/- mice after SNL [124]. 24
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TRAAK knockout mice, like TREK-1 knockouts, had normal cold-sensitive C-fibres and 1
no cold sensing deficits in the cold plate assay, the temperature-preference assay from 27 °C 2
to 12 °C, or in cold allodynia following CCI [62]. A cold sensing phenotype became apparent 3
only when both TREK1 and TRAAK were removed. The double knockout mice showed cold 4
hypersensitivity in the 30°C thermal preference test, increased cold avoidance in the cold plate 5
test, and increased cold allodynia post-CCI [62]. Thu,s during cold allodynia, where normally 6
silent sensory neurons increasingly respond to mild cooling, reduced background potassium 7
conductance may contribute to altered thermal thresholds and heightened cold sensitivity.8
The presence of 4-aminopyridine-sensitive Kv channels appears to define cold-insensitive 9
neurons [61, 121]. Activity of these channels prevents firing of cold-insensitive neurons 10
during cooling by acting as excitability brakes. In addition, the setting of the temperature 11
threshold in cultured trigeminal neurons is conferred by equilibrium between TRPM8 and Kv1 12
channels. Indeed, the temperature threshold of trigeminal neurons is defined by balanced 13
expression of the cold-sensitive thermosensor TRPM8 and Kv1 channels, with cold-sensitive 14
neurons defined by large TRPM8-mediated responses and low Kv1 current density, while the 15
inverse relationship is true for cold-insensitive neurons [61].16
Investigating ion channel constellations in low- and high-threshold cold-sensitive DRG 17
neurons revealed that Kv1.1 and Kv1.2 selective blockers increased baseline calcium levels of 18
high-threshold cold sensors but not low-threshold sensors, confirming differential expression 19
of Kv1 channels in cold-sensitive neurons responsive to different temperature ranges [85]. 20
Selective Kv1.2 block converted high-threshold cold sensors into low-threshold cold sensors 21
that respond to minor fluctuations in temperature (± 1 °C) [85]. This effect translates to 22
increased nocifensive behaviour of mice on a 0 °C cold plate and increased flinching in the 23
acetone test after intraplantar injection of a Kv1 channel blocker [61]. These results support a 24
pivotal role of Kv1 channels in setting the temperature threshold of cultured DRGs with high, 25
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but not low threshold, cold-sensitivity. Whether Kv1 channels also contribute to the setting of 1
the temperature thresholds, and thereby shape the broad dynamic range of monomodal cold-2
sensitive fibres in the murine skin, has not been investigated so far. 3
A similar inverse relationship exists for Kv7 availability and temperature threshold of 4
activation in cutaneous cold nociceptive nerve fibre terminals [60]. While Kv7 expression 5
levels or current density cannot be determined in terminal nerve endings, the cold sensitising 6
effect of the Kv7 inhibitors XE991 and camphor were directly correlated to the fibre’s 7
temperature threshold, with low threshold cold-sensitive fibres showing little cold sensitisation 8
in response to Kv7 inhibition [60]. Instead, relatively cold-insensitive fibres with high 9
temperature thresholds showed pronounced cold sensitisation in response to both camphor and 10
XE991 [60]. However, treatment with the Kv7 specific inhibitor XE991 or camphor, an M-11
channel inhibitor and weak TRPM8 agonist, were unable to trigger a cold response in the 12
absence of TRPM8, suggesting that Kv7 channels act as suprathreshold amplifiers of the cold-13
activated generator potential provided by TRPM8 [60]. In addition, menthol appears to be an 14
M-channel inhibitor and thus combines dual cold-activating and cold-sensitising 15
pharmacology in one molecule [60]. 16
17
Animal Models of Cold Pain18
Rodent models are widely used to assess the contribution of various ion channels to cold 19
sensing and nociception as well as cooling-induced allodynia and hyperalgesia, largely due to 20
the accessibility of rodents in a laboratory setting and the ease of genetic manipulation in mice 21
in particular. However, results from rodent studies, especially mice, are limited by difficulties 22
relating to behavioural responses to pain sensation in animals, with poor distinction often 23
made between innocuous cool, cold and noxious cold. Overt aversive behaviours upon 24
exposure to temperature-controlled surfaces such as paw lifting, licking, flinching, shaking or 25
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jumping occur at temperatures below 5 °C, suggesting this should be considered the threshold 1
for noxious cold in rodents [19]. Moreover, large variation in response latency occurs in the 2
traditional measure of hind paw withdrawal upon contact with a 0 °C cold plate, which can 3
range from 5-200 seconds in several independent reports [63-65, 78]. Attempts to correlate 4
more subtle changes in exploratory behaviour, such as walking backwards, to cold-induced 5
pain responses have been reported [125]. Nevertheless, the validity and reproducibility of such 6
approaches are unclear. An alternative approach to quantification of cold-induced pain 7
behaviour is to assess latency to forepaw rather than hind paw withdrawal or shaking, an 8
approach used successfully to assess the contribution of TRPM8 to noxious cold sensing at 0 9
°C [66, 82].10
Another measure of cold avoidance is the temperature preference assay. The two-plate 11
temperature preference assay allows animals to choose between two adjacent surfaces 12
maintained at different temperatures, while the temperature gradient assay determines a 13
preference temperature directly by using a continuous gradient. In these assays, choosing the 14
appropriate temperature range is crucial as differences in phenotype or behaviour can only be 15
detected if the thermal environment lies in the appropriate range of being mildly aversive 16
without being overtly noxious. However, although clear differences in time spent at cool 17
temperatures are apparent in models such as TRPM8-/- animals, it is not entirely clear to what 18
degree these assays reflect physiological warmth preference rather than a sensation of pain, or 19
aversion to cool. 20
The acetone test consists of applying a drop or a small spray of acetone to one hind paw, 21
which then leads to evaporation-induced cooling and aversive behaviour. Application of 22
acetone to the hind paw is often considered an innocuous cold stimulus as a decrease of 23
approximately ~8-12 °C in skin temperature can be achieved with this technique [64, 126]. An 24
additional advantage of the acetone test is the ability to stimulate unilateral aversive 25
Page 19 of 50
Ac
ce
pte
d M
an
us
cri
pt
19
behaviour, which may be easier to quantify. However, application of acetone to the hind paw 1
of mice, and to a lesser degree of rats, elicits withdrawal responses in some naïve animals 2
[64], suggesting the use of the acetone evaporation test is not suitable for quantification of 3
cold allodynia and may more accurately represent general noxious withdrawal responses. 4
Acetone-evoked withdrawal responses may also incorporate elements of mechanical 5
stimulation or aversive responses to the odour of acetone, and control over the rate and degree 6
of cooling is not possible. In addition, acetone has high vapour pressure and a small surface 7
tension, and forming a uniform “drop” on a syringe that can be applied to the animal’s hind 8
paw can rarely be achieved. 9
An additional factor to be considered in observer-based behavioural studies is the need for 10
appropriate blinding and randomisation to eliminate conscious, as well as unconscious, bias. 11
This is illustrated by our observation that cold allodynia was erroneously observed when a 12
blinded observer quantified paw withdrawal responses to the application of acetone between 13
two distinct groups of mice while knowing one group was an experimental cohort and the 14
other a control cohort.  This effect completely disappeared when individual mice from the two 15
cohorts were observed at random (unpublished observation). 16
Despite the wide availability of animal models of cold allodynia, it is difficult to evaluate 17
how well the pathophysiological mechanisms of animal models translate to human conditions. 18
This difficulty arises in part from differences in the time course of disease and methods used 19
to induce and measure pain behaviour. Currently, animal models are considered adequate as 20
long as the animals exhibit similar neuropathic pain symptoms to human patients after 21
exposure to the same chemicals or injuries. The extent to which such animal models are based 22
on similar disease mechanism as their human equivalents is not always clear and needs to be 23
assessed using well-designed clinical studies.24
25
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Treatment of Pathological Cold Pain1
Despite our growing understanding of the pathophysiology of cold pain, treatment of 2
neuropathic cold pain remains largely symptomatic, with standard analgesics and adjuvants 3
used in the majority of conditions associated with cold allodynia or hyperalgesia. 4
Neuropathic pain patients often present with a multitude of sensory abnormalities that are 5
based on diverse pathophysiological mechanisms. Most clinical trials assessing analgesic 6
efficacy for specific diseases rely on visual analogue scales or equivalent self-reporting of pain 7
intensity rather than quantitative sensory testing. In addition, co-morbidities are common in 8
diseases that present with cold allodynia, adding to heterogeneity in the clinical presentation. 9
Accordingly, delineating clinical efficacy for treatment of cold pain specifically is often 10
difficult, although inclusion of quantitative sensory profiling in clinical trials is likely to 11
improve our success in mechanism-based treatment approaches [127]. 12
As outlined in the preceding sections, it is becoming increasingly clear that cold pain and 13
cold sensing are complex phenomena involving diverse modality- and disease-specific 14
mechanisms. This complexity is illustrated by the diverse molecular mechanisms underlying 15
cold pain induced by intraplantar injection of ciguatoxin and oxaliplatin. While ciguatoxin-16
induced cold allodynia requires TRPA1 and is decreased significantly without functional 17
Nav1.8, acute oxaliplatin-induced cold allodynia develops in sensory neurons expressing TTX-18
sensitive Nav1.6 independent of thermosensitive TRP channels. It is thus likely there will be 19
no single molecular target or drug that can treat the wide pathophysiological spectrum of cold 20
allodynia and hyperalgesia. Nonetheless, mechanism-directed drug therapy for neuropathic 21
pain is on the rise, with drugs targeting TRPA1 and TRPM8 as well as Nav1.8 and Nav1.7 22
considered particularly attractive for treatment of cold pain, albeit the responding patient 23
populations will need to be chosen carefully based on the underlying pathophysiological 24
mechanisms. Based on the role of K+ channels in setting the temperature threshold in cold-25
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sensitive peripheral sensory neurons, K+ channel agonists may also prove useful in the clinical 1
management of neuropathic cold pain. Indeed, the K+ channel agonists flupirtine and 2
retigabine were effective at decreasing neuronal excitability in an in vitro model of 3
oxaliplatin-induced cold hypersensitivity and also decreased oxaliplatin-induced cold 4
allodynia in vivo, as did analgesics with mixed activity at Nav and Kv channels such as 5
lamotrigine and phenytoin (See Table 12) [128, 129].6
Although selective channel modulators may be a feasible strategy for reducing cold 7
allodynia due to the defined role of many channels such as TTX-sensitive Nav isoforms, 8
Nav1.8, TRPM8 and TRPA1, limited research on the clinical applications of these findings is 9
available and accurate analgesic efficacy prediction based on cell or rodent models may be 10
difficult. For example, while amitriptyline reduced ciguatoxin-induced calcium influx in in 11
vitro models, it was not effective at treating ciguatoxin-induced cold allodynia in a rodent 12
model [37]. In the absence of systematic clinical trials in human ciguatera sufferers, this result 13
is consistent with an anecdotal report of lack of efficacy of amitriptyline for treatment of cold 14
hypersensitivity, although the tricyclic antidepressant may be efficacious at treating other 15
symptoms associated with ciguatera [130]. Conversely, the antiepileptic lamotrigine and the 16
analgesic flupirtine were analgesic in vivo but had little effect on ciguatoxin-induced Ca2+17
responses in vitro, being 100- and 10-times less potent than amitriptyline, respectively [37].  18
A similar analgesic efficacy profile was observed for oxaliplatin-induced cold allodynia, 19
with lamotrigine, retigabine, and phenytoin being most effective while amitriptyline was not 20
analgesic [128, 131]. Gabapentin as well as Ca2+/Mg2+ also partially reduced oxaliplatin-21
induced cold allodynia [131]. However, while efficacy of Ca2+/Mg2+ is in accordance with 22
several clinical studies [132-134], gabapentin was not effective in a randomised controlled 23
trial on oxaliplatin-induced neuropathic pain [135]. In fact, more patients in the gabapentin 24
treatment group developed neuropathy than those in the control group [135]. This apparent 25
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discrepancy highlights the difficulty in translating findings from cellular models to murine 1
models and human disease. Similarly, venlafaxine displayed effective analgesia in a murine 2
model of oxaliplatin-induced cold allodynia [136], yet did not significantly improve cold 3
allodynia in human patients despite efficacy towards other symptoms of oxaliplatin-induced 4
neuropathy [137]. Curiously, morphine treatment displayed significant benefit in murine 5
models of acute and chronic oxaliplatin-induced cold allodynia [136, 138], while the opioid 6
receptor agonist fentanyl was ineffective at reversing cold allodynia induced by intraplantar 7
injection of oxaliplatin [128].8
Few human studies have specifically examined analgesic efficacy in paclitaxel-induced 9
cold allodynia. Randomised controlled trials assessing the effect of gabapentin, lamotrigine 10
and glutathione found a lack of efficacy in chemotherapy-induced peripheral neuropathy 11
(CIPN) [139-141]. However, these studies did not specifically investigate cooling-related 12
symptoms. Currently, the most promising treatment targeting paclitaxel-induced cold 13
allodynia that has undergone human trials appears to be duloxetine. In one case study, a 14
patient complaining of persistent and uncontrolled paclitaxel-induced neuropathy was treated 15
unsuccessfully with pregabalin and trazodone. The addition of duloxetine reversed the 16
symptoms and the patient experienced almost no pain two and half months later [142]. While 17
this case study did not specify what type of allodynia the patient suffered from, evidence from 18
a murine model supported the lack of efficacy of pregabalin in cold allodynia after paclitaxel 19
administration [143], while a clinical trial showed duloxetine to be efficacious in CIPN [144]. 20
This suggests that duloxetine, but not pregabalin, may be a potential treatment for paclitaxel-21
induced cold allodynia, although further studies are warranted.  22
In comparison to studies on CIPN, a much larger body of literature is devoted to the current 23
and prospective treatments for diabetic neuropathy. A vast array of drugs, ranging from tight 24
control of blood glucose levels  to topical capsaicin applications, are used clinically to treat 25
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pain and allodynia associated with diabetic neuropathy. Cold allodynia, however, does not 1
present in every case of diabetic neuropathy. Moreover, human clinical trials on diabetic 2
neuropathy frequently use pain scores and visual analogue scales as measurements of 3
analgesia and do not necessarily assess the extent of stimulus-evoked pain or cold allodynia. 4
Trials that include cold pain patients also often do not report separate analysis of modality-5
specific pain [145, 146]. Therefore, it is often difficult to gauge the specific impact of 6
treatments on cold pain. Notably, clinical studies on lamotrigine, gabapentin, and amitriptyline 7
specified the inclusion of cold pain patients, and the overall results were positive [147, 148]. A 8
rat study also verified that amitriptyline is effective in diabetic animals with associated cold 9
allodynia [149]. However, while venlafaxine and pregabalin were effective for the treatment 10
of diabetic neuropathy, it is unclear if these human trials included patients with cold pain [146, 11
150]. 12
Unlike the peripheral neuropathies that are associated with cold pain, central post-stroke 13
pain (CPSP) triggers cold pain through damage to central pain tracts. Its treatment broadly 14
follows that of other neuropathies, with drugs such as pregabalin and amitriptyline effectively 15
alleviating neuropathic pain [151, 152]. While systematic clinical trials assessing analgesic 16
efficacy in CPSP-associated cold pain are largely lacking, treatment with duloxetine for eight 17
weeks significantly decreased cold allodynia evoked by the acetone test in humans [153]. 18
Therefore, while CPSP in general can be effectively treated by a variety of drugs commonly 19
used in neuropathic pain, duloxetine appears as a promising new treatment of cold allodynia 20
associated with central nerve injury.21
With increasing understanding of the pathophysiological mechanisms underlying cold pain, 22
new mechanism-based treatments are being developed. Extensive drug discovery efforts 23
directed at thermosensitive ion channels, most notably TRPA1 and TRPM8, have led to the 24
discovery of a number of molecules with putative analgesic efficacy in cold allodynia. HC-25
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030031, a purine acetamide and selective TRPA1 antagonist, has been used extensively in a 1
range of models associated with cold pain (see Table 5), with variable effects. Notably, HC-2
030031 was effective in rodent models of nerve injury and inflammation [83, 154], as was 3
another small molecule TRPA1 inhibitor, A-967079 [155].4
Presently, a TRPA1 selective antagonists (GRC 17536) is being evaluated in human studies 5
for the treatment of diabetic neuropathy and reached Phase II trials 6
(http://clinicaltrials.gov/ct2/show/NCT01726413), and further Phase I clinical trials have been 7
initiated to assess safety and efficacy of the TRPA1 antagonist CB-625 [156]. In addition, a 8
range of TRPM8 antagonists are being developed currently,  including compounds that 9
showed efficacy in rodent models of chronic constriction injury- and oxaliplatin-induced cold 10
allodynia [157]. Other selective TRP as well as Na+ or K+ channel modulators remain in the 11
pre-clinical development stage where their efficacy, selectivity, and dose in vitro and in vivo12
remain a topic of investigation. Thus, promising new approaches to the treatment of cold pain 13
are on the horizon.14
15
Conclusion16
This review has highlighted that cold pain and cold sensing are complex phenomena, with 17
clear differences in molecular pathophysiology between conditions associated with cold pain. 18
Peripheral sensory neuron ion channels, such as voltage-gated sodium channels, potassium 19
channels, and TRP channels, are involved to varying degrees in cold nociception, 20
hyperalgesia and allodynia and may be suitable targets for improved treatment of these pain 21
modalities. Notably, in addition to Nav1.7, Nav1.8, TRPA1, TRPM8, Kv1, TRESK, and 22
TRAAK, more recently Kv7.2/7.3, TRPC5, and Nav1.6 have also been implicated in cold 23
sensing and pain. In light of the diverse molecular players and mechanisms involved in 24
pathological cold pain, it is not surprising that there is currently no universally effective 25
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treatment. In addition, the cold pain symptoms present in each neuropathic syndrome are 1
likely to result from specific sets of interactions between peripheral fibres, ion channels, and 2
central modulation. Given this complexity, extensive research is required to unravel the 3
processes underlying neuropathic cold pain and to allow the rational development of new 4
drugs that improve the clinical management of this often-neglected syndrome.5
6
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Table 1. Peripheral nerve subtypes involved in sensing innocuous and noxious cold1
Fibre type Fibre subtype Sensitivity References
CC (C-cold) Only respond to cold, menthol-
sensitive
[3, 6, 15, 102, 
158]
CMHC (C-mechano-heat-
cold)
Polymodal nociceptors,  
respond to noxious mechanical, 
heat and cold
[14, 60, 159]
CMC (C-mechano-cold) Polymodal nociceptors,  
respond to noxious mechanical 
and cold
[13, 60, 158, 
159]
C-fibres
High-threshold cold-
sensitive fibres
Only respond to noxious cold 
(< 20 °C)
[7]
Low-threshold cold-
sensitive fibres 
Respond to innocuous cold [160]
AδMHC (Aδ-mechano-
heat-cold)
Polymodal nociceptors,  
respondto noxious mechanical, 
heat and cold
[13, 159]
AδMC (Aδ-mechano-
cold) fibres
Polymodal nociceptors, 
respondg to noxious mechanical 
and cold
[159]
Aδ-fibres
Mechano-insensitive 
cold-sensitive fibres 
Respond to innocuous or 
noxious cold
[6, 160]
2
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Table 2. Common neuropathic pain conditions exhibiting symptoms of cold allodynia1
Conditions associated with Pathological 
Cold Pain 
Cold Pain Prevalence
Ciguatera 71-88% [161-163]
Oxaliplatin-induced neuropathy 81-98% [164]
Paclitaxel-induced neuropathy 84% [165]
Diabetic neuropathy Uncertain
Central  post-stroke pain (CPSP) 17-70% [166-168]
Post-traumatic cold intolerance following 
upper limb injury
38-82% [52, 54, 55]
2
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Table 3. TRPM8 in in vivo behavioural models of cold pain1
2
Model Pain test Inhibition Cold 
sensitivity
Species Ref
Nociception
Acetone test KO Reduced Mouse
Temperature preference 
test (30 °C vs 25-5 °C)
KO Reduced Mouse
10 °C, 0 °C, -5 °C and -
10 °C cold plates
KO Reduced Mouse
[63]
0 °C cold plate. 
Temperature preference 
test (room temperature vs 
25/5 °C)
KO Reduced Mouse [64]
15 – 53.5 °C multi-zone 
plate
KO Reduced Mouse
Acetone test KO Reduced Mouse
-1°C cold plate KO Unchanged Mouse
Icilin (intraperitoneal) KO Reduced Mouse
[65]
Acetone test
Icilin (intraperitoneal)
0 °C cold plate
Temperature preference 
test (5-50 °C)
KO Mouse
Acetone test
Icilin (intraperitoneal)
0 °C cold plate
Paw
Temperature preference 
test (5-50 °C)
TRPM8-positive 
DRG neurons 
ablated by 
diphtheria toxin
Reduced
Mouse
[66]
Inflammation
Acetone test KO Reduced Mouse [64]
Acetone test KO Reduced Mouse
Complete 
Freund’s 
Adjuvant 
injection 
(CFA)
Acetone test TRPM8-positive 
DRG neurons 
ablated by 
diphtheria toxin
Reduced Mouse
[66]
Nerve injury
Acetone test KO Reduced Mouse [64]
Acetone test KO Reduced Mouse
Acetone test TRPM8-positive 
DRG neurons 
ablated by 
diphtheria toxin
Reduced Mouse
[66]
4 °C cold plate Local KO with 
oligonucleotides
Reduced Rat
4 °C cold plate Menthol 
(intrathecal)
Increased Rat
[67]
CCI
1-cm-deep 4 °C water on 
cage floor
Local KO with 
oligonucleotides
Reduced Rat [169]
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Neuropathies
15 °C cold plate KO Unchanged MouseCiguatoxin
15 °C cold plate AMTB (intraplantar) Unchanged Mouse
[38]
Temperature 
preference test 
(25 °C vs 
21/23 °C)
KO Reduced Mouse [42]
10 °C cold plate KO Unchanged Mouse
10 °C cold plate AMTB (intraplantar) Unchanged Mouse
10 °C cold plate M8-B (intraplantar) Unchanged Mouse
[39]
Acetone test Capsazepine 
(intraperitoneal)
Reduced Mouse [43]
Oxaliplatin
Acetone test Capsazepine 
(intraperitoneal)
Unchanged Mouse [40]
1
2
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Table 4. TRPA1 in in vitro models of cold pain1
Model Species Temp Respond 
to cold
Comment Ref
Mouse 9 °C Yes Increased inward current [77]
Mouse 10 °C Yes Inward current increase [82]
CHO cells
Mouse 17 –11 °C Yes Calcium influx and inward 
current increase
[59]
Human 5 °C Yes Increased inward current
Mouse 5 °C Yes Increased inward current
[77]
Rattlesnake 15 – 45 °C No
Rat snake 15 – 45 °C No
Drosophila 15 – 45 °C No
Human 15 – 45 °C No
Rattlesnake, rat snake, 
Drosophila TRPA1 
responded to >38°C. 
Human TRPA1 responded 
to neither heat or cold
[87]
Xenopus
oocytes 
Mouse 5 °C Yes Inward current increase [59]
Rat 10 °C Yes Increased inward current [83]
Rat 24 – 8 °C Yes
Mouse 24 – 8 °C Yes
Human 24 – 8 °C No
Rhesus monkey 24 – 8 °C No
Calcium infl x and inward 
current increased for rat 
and mouse TRPA1, but not 
for human or Rhesus 
monkey TRPA1
[81]
Mouse 16 – 5 °C Yes Calcium influx and inward 
current increase
[84]
Human 10 °C No Calcium influx increased 
for both TRPA1-positive 
and control cells upon cold 
stimulation
[88]
HEK cells
Human 5 °C No No calcium influx [74]
Rat 10 °C Yes Increased inward current [83]
Mouse 16 – 5 °C Yes Calcium influx increase [84]
Rat 17/5 °C Yes
Cultured 
DRG 
neurons
Mouse 17/5 °C No
Many rat cold-sensitive 
neurons express TRPA1,  
very few mouse cold 
sensors express the channel
[85]
Mouse 16 – 8 °C No No increase in calcium 
influx
[61]
Mouse 25 – 10 °C Yes Calcium influx increase [82]
Cultured 
trigeminal 
neurons
Rat 5 °C No No cold response in 
neurons responsive to 
mustard oil
[74]
Nodose 
ganglion 
neurons
Rat 12 °C Yes Ca2+ responses and 
currents in vagal neurons
[86]
2
3
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Table 5. TRPA1 in in vivo behavioural models of cold pain1
Model Pain test Inhibition Cold sensitivity Species Ref
Nociception
0 °C cold plate KO Reduced Mouse
-5 °C cold plate HC-030031 
(intraperitoneal)
Unchanged Rat
[83]
0 °C cold plate KO Reduced Mouse [82]
10 °C cold plate KO Reduced Mouse [170]
Acetone test KO Reduced Mouse [170]
Paw
5 – 0 °C cold 
plate
A-967079 (oral) No effect Mouse [155]
Tail -10 °C tail 
immersion
KO Reduced Mouse [82]
Inflammation
5 °C cold plate HC-030031 
(intraperitoneal)
Reduced Rat [83]CFA
5 °C cold plate. 
Hind paw 
immersion in 
water at 28 °C, 
16 °C, and 4 °C
Local KO with 
oligonucleotides
Reduced Rat [171]
Nerve injury
CCI Acetone test A-967079 (oral) Reduced Rat [155]
10 °C cold plate HC-030031 
(intraperitoneal)
Reduced Rat [83]
5 °C cold plate Local KO with 
oligonucleotides
Reduced Rat [172]
SNL
5 °C cold plate. 
Hind paw 
immersion in 
water at 28 °C, 
16 °C, and 4 °C
Local KO with 
oligonucleotides
Reduced Rat [171]
Neuropathies
Ciguatoxin 15 °C cold plate KO Reduced Mouse [38]
10 °C tail 
immersion
HC-030031 
(intragastric)
Reduced Rat
Acetone test KO Reduced Mouse
[40]
10 °C cold plate HC-030031 
(intraplantar)
Unchanged Mouse
10 °C cold plate KO Unchanged Mouse
[39]
Oxaliplatin
30–1 °C 
dynamic cold 
plate
HC-030031 
(intraperitoneal)
Unchanged Mouse [42]
2
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Table 6. Nav1.7 in in vivo behavioural models of cold pain 1
Model Pain test Inhibition Cold sensitivity Species Reference
Nociception
Acetone test Nav1.7
Advill Reduced Mouse
Temperature 
preference test 
(30 °C and 5 °C 
cold plates)
Nav1.7
Advill Unchanged Mouse
Acetone test Nav1.7
Nav1.8 Unchanged Mouse
Temperature 
preference test 
(30 °C and 5 °C 
cold plates)
Nav1.7
Nav1.8 Unchanged Mouse
Acetone test Nav1.7
Wnt1 Reduced Mouse
Paw
Temperature 
preference test 
(30 °C and 5 °C 
cold plates)
Nav1.7
Wnt1 Unchanged Mouse
[110]
Nerve injury
Acetone test Nav1.7
Advill Unchanged Mouse
Acetone test Nav1.7
Nav1.8 Unchanged Mouse
Spare nerve 
injury 
(SNI) Acetone test Nav1.7
Wnt1 Reduced Mouse
Acetone test Nav1.7
Advill Reduced Mouse
Acetone test Nav1.7
Nav1.8 Reduced Mouse
CCI
Acetone test Nav1.7
Wnt1 Reduced Mouse
[111]
Neuropathies
Ciguatoxin 15 °C cold plate ProTxII 
(intraplantar)
Unchanged Mouse [37]
Acetone test Nav1.7
Wnt1 Unchanged Mouse [111]Oxaliplatin
10 °C cold plate ProTxII 
(intraplantar)
Unchanged Mouse [39]
2
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Table 7. Nav1.8 in in vivo behavioural models of cold pain 1
Model Pain test Inhibition Cold sensitivity Species Reference
Nociception
Temperature 
preference test 
(30 °C and 
5 °C cold 
plates)
KO Reduced Mouse
Acetone test KO Unchanged Mouse
[110]
0 °C cold plate KO Reduced Mouse [112]
Paw
0 °C cold plate Nav1.8-
positive DRG 
neurons 
ablated by 
diphtheria 
toxin
Reduced Mouse [113]
Nerve injury
Acetone test KO Unchanged Mouse [111]SNI
Acetone test KO Reduced Mouse [173]
Acetone test KO Reduced Mouse [111]CCI
Acetone test KO Unchanged Mouse [173]
Neuropathies
15 °C cold 
plate
A803467 
(intraplantar) 
Reduced Mouse
15 °C cold 
plate
Nav1.8-
positive DRG 
neurons 
ablated by 
diphtheria 
toxin
Reduced Mouse
Ciguatoxin
15 °C cold 
plate
KO Reduced Mouse
[38]
Oxaliplatin 15 °C cold 
plate
A803467 
(intraplantar)
Unchanged Mouse [37]
2
3
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Table 8. Nav1.3 in in vivo behavioural models of cold pain 1
Model Pain test Inhibition Cold 
sensitivity
Species Reference
Nerve injury
Acetone test KO Unchanged Mouse [111]SNI
Acetone test Intrathecal 
injection of 
oligonucleotides
Unchanged Rat [174]
CCI Acetone test KO Reduced Mouse [111]
Neuropathies
Ciguatoxin 15 °C cold 
plate
KO Unchanged Mouse [37]
Oxaliplatin 10 °C cold 
plate
KO Unchanged Mouse [39]
2
Table 9. Nav1.6 in in vivo behavioural models of cold pain3
4
Model Pain test Inhibition Cold sensitivity Species Reference
Neuropathies
Ciguatoxin 15 °C cold 
plate
GIIIA 
(intraplantar) 
Reduced Mouse [37]
Oxaliplatin 10 °C cold 
plate
GIIIA 
(intraplantar)
Reduced Mouse [39]
5
Table 10. Nav1.9 in in vivo behavioural models of cold pain6
7
Model Pain test Inhibition Cold sensitivity Species Reference
Nociception
Paw 0 °C cold 
plate
KO Unchanged Mouse [175]
Nerve injury
Acetone test KO Unchanged Mouse [111]SNI
Acetone test KO Reduced Mouse [173]
Acetone test KO Reduced Mouse [111]CCI
Acetone test KO Reduced Mouse [173]
Neuropathies
Ciguatoxin 15 °C cold 
plate
KO Unchanged Mouse [38]
Oxaliplatin 10 °C cold 
plate
KO Unchanged Mouse [39]
8
9
10
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Table 11: Comparison of animal cold allodynia models with human disease1
Causes of 
disease
Disease time 
course 
Acute Symptoms Chronic 
symptoms
Diabetic neuropathy-induce cold allodynia
Animal 
model
Streptozotocin-
induced 
hyperglycaemia
21 days from 
streptozotocin 
injection to 
hyperglycaemia 
[45, 176]
N/A Cold allodynia, heat 
allodynia, heat 
hyperalgesia, 
mechanical 
hyperalgesia [176]
Animal 
model
Zucker Fatty 
rats
Hyperglycaemia 
established from ~8 
weeks [177]
N/A Reduced nerve 
conduction speed, 
mechanical 
allodynia [177]
Human 
patients
Chronic diabetes 
mellitus type 1 
or 2
A minimum of 6 
months to 2 years 
from diabetes 
diagnosis to 
established 
neuropathy, 
dependent on 
hyperglycaemia 
[147, 150, 178]
N/A Peripheral pain, 
tingling, 
paraesthesia, 
numbness, reduced 
vibration perception, 
nerve conduction 
abnormalities [147, 
178]
Ciguatera
Animal 
model
Ciguatoxin 
(intraplantar)
Immediate [38] Spontaneous pain, 
cold allodynia [38]
N/A
Animal 
model
Ciguatoxin 
(intraperitoneal)
Immediate [179] Hypothermia, 
reduced locomotor 
activity, 
hyporeflexia, 
lachrymation, 
salivation, 
diarrhoea
N/A
Human 
patients
Ingestion of 
ciguatoxin-
contaminated 
fish
Immediate [161] Paraesthesia, 
diarrhoea, 
abdominal pain, 
vomiting, headache 
[161]
Paraesthesia, 
myalgia, muscle 
weakness, vertigo, 
ataxia [161]
Oxaliplatin-induced cold allodynia
Animal 
model
Injected 
oxaliplatin 
(acute or 
chronic)
Immediate [39] Cold allodynia, 
mechanical 
allodynia [39, 180]
Mechanical 
allodynia, cold 
allodynia [136]
Human 
patients
Chronic 
oxaliplatin 
therapy
Immediately after 
injection [181] and 
chronic
Peripheral 
paraesthesia and 
cold allodynia 
[181]
Cold and heat 
allodynia, impaired 
vibration detection 
[181]
2
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Table 12. Common drugs used in the treatment of neuropathic cold allodynia1
Drug name Drug Target Condition Effect Structure References
Ciguatera Uncertain [37, 163]
Oxaliplatin-
induced 
No [128, 131]
Amitriptyline Serotonin-
noradrenaline 
reuptake 
inhibitor and 
Nav inhibitor 
[182]
Diabetic 
neuropathy 
Yes [148, 149]
Paclitaxel-
induced
Yes [142, 144]Duloxetine Serotonin-
noradrenaline 
reuptake 
inhibitor
Post-
stroke centr
al pain
Yes [153]
Venlafaxine Serotonin-
noradrenaline 
reuptake 
inhibitor
Oxaliplatin-
induced 
Uncertain [136, 137]
Oxaliplatin-
induced
Uncertain [138, 143]Pregabalin Cav in the 
CNS
Paclitaxel-
induced
No [142, 143]
Oxaliplatin-
induced 
Uncertain [129, 131, 
135, 136, 
139]
Gabapentin Cav inhibitor 
[183]
Diabetic 
neuropathy 
Yes [148]
Ciguatera Yes [37]
Oxaliplatin-
induced
Yes [128]
Lamotrigine Nav, Cav
inhibitor,  Kv
activator 
[184] Diabetic 
neuropathy 
Yes [147]
Ciguatera Yes [37]Phenytoin Nav inhibitor 
Oxaliplatin-
induced
Yes [128]
Ciguatera Yes [37]Flupirtine Kv activator
Oxaliplatin-
induced
Yes [129]
Retigabine Kv7 activator Oxaliplatin-
induced
Yes [128]
Ca2+/Mg2+
infusion
Chelation to 
oxaliplatin 
metabolite, or 
Nav inhibition
Oxaliplatin-
induced 
Yes [131-134]
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Morphine µ-opioid 
receptor 
agonist
Oxaliplatin-
induced
Yes [136, 138]
1
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Fig. 1. Ion channels involved in cold sensing and cold pain. A range of neuronal ion 1
channels have been identified that differentially contribute to physiological cold sensing, cold 2
nociception, as well as pathological cold pain states such as cold allodynia and cold 3
hyperalgesia. Transient receptor potential channels TRPA1, TRPM8 and TRPC5 are gated by 4
cold and are involved in transformation of an external thermal stimulus into a neuronal signal. 5
Voltage-gated potassium channels, most notably Kv1 and Kv7.2/7.3, act as excitability brakes 6
in cold-insensitive neurons and contribute to setting the temperature threshold. In addition, 7
background potassium channels such as TRAAK and TREK-1, which regulate the resting 8
membrane potential of sensory neurons, are instrumental in reducing neuronal excitability and 9
thus contribute crucially to thermal pain. Voltage-gated sodium channels, including Nav1.7 10
and Nav1.8 are expressed in unmyelinated nociceptive fibres and contribute to neuronal 11
depolarisation and hyper-excitability. 12
13
Fig. 2. Pharmacology of cold pain pathways. The molecular mechanisms that integrate to 14
produce cold pain in different disease states are diverse. These include altered signal 15
transduction in myelinated and unmyelinated peripheral sensory nerve endings, altered action 16
potential (AP) propagation, and altered spinal transmission and central processing. Key 17
channels and receptors contributing to physiological and pathological cold pain pathways are 18
illustrated.19
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